We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

McNeil Healthcare (Ireland) Ltd

Airton Road, Tallaght, Dublin 24, Ireland
Telephone: +353 1 466 5200
Fax: +353 1 466 5316

Summary of Product Characteristics last updated on medicines.ie: 12/10/2015
SPC Imodium Capsules

Go to top of the page

Imodium 2 mg Capsules.

Go to top of the page

Each capsule contains 2 mg of loperamide hydrochloride.

Excipients: Each capsule contains 127 mg lactose.

For a full list of excipients, see section 6.1.

Go to top of the page

Capsule, hard. (capsule)

Gelatin capsules with an opaque green cap and an opaque dark grey body, containing white powder.

Go to top of the page

Go to top of the page
4.1 Therapeutic indications


As an adjunct in the management of acute diarrhoea, together with appropriate fluid and electrolyte replacement.

In the symptomatic control of diarrhoea associated with chronic inflammatory bowel disease, e.g., Crohn's disease and ulcerative colitis, as an adjunct to specific measures such as corticosteroids and sulphasalazine. Use in these conditions should be under specialist supervision.

In the adjunctive short-term, control of post-surgical diarrhoea, including ileostomy.


For the occasional use in the control of intractable diarrhoea under specialist supervision.

Since persistent diarrhoea can be an indicator of potentially serious conditions, the underlying cause must always be investigated.

Go to top of the page
4.2 Posology and method of administration

For oral administration.The capsules should be taken with water.

i) As an adjunct in the management of acute diarrhoea

Adults and children 9-12 years

2 to 4 mg is the usual initial dose, followed by 2 mg three times daily. The maximum daily dose should not exceed 10 mg.

Children 4-8 years

A total maximum daily dose of 4 mg in divided doses.

Under 4 years

Not recommended.

Use in elderly

No dose adjustment is required for the elderly.

Renal impairment

No dose adjustment is required for patients with renal impairment.

Hepatic impairment

Although no pharmacokinetic data are available in patients with hepatic impairment, Imodium should be used with caution in such patients because of reduced first pass metabolism (see 4.4 Special warning and precautions for use).

ii) For the symptomatic treatment of diarrhoea associated with chronic bowel disorders

Adults only

Studies have shown that patients may need differing amounts of loperamide. The starting dosage should be between 4 to 8 mg (2 to 4 capsules) per day in divided doses depending on severity. If required, this dose can be adjusted according to response. Having established the patient's daily maintenance dose, the capsules may be administered on a twice daily regimen.

Go to top of the page
4.3 Contraindications

• Imodium is contraindicated in patients under 4 years of age

• Imodium is contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients

• Imodium should not be used as the primary therapy:

- In patients with acute dysentery, which is characterised by blood in the stools and high fever

- In patients with acute ulcerative colitis

- In patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella, and Campylobacter

- In patients with pseudomembranous colitis associated with the use of broad spectrum antibiotics.

• Imodium should not be used when the inhibition of peristalsis is to be avoided due to the possible risk of significant sequelae including ileus, megacolon and toxic megacolon. Imodium must be discontinued promptly when constipation, abdominal distension or ileus develop

Go to top of the page
4.4 Special warnings and precautions for use

Treatment of diarrhoea with loperamide HCl is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate.

The necessity for specific therapy, such as anti-infectives, should be borne in mind, particularly should treatment be required for a period longer than three days.

Loperamide should be used with caution when hepatic function, necessary for the drug's metabolism, is defective, as this may result in relative overdose leading to CNS toxicity.

Patients with AIDS treated with Imodium for diarrhoea should have therapy stopped at the earliest signs of abdominal distension. There have been isolated reports of toxic megacolon in AIDS patients with infectious colitis from both viral and bacterial pathogens treated with loperamide hydrochloride.

Antimotility agents such as loperamide may precipitate ileus and toxic megacolon in patients with ulcerative colitis, and should be avoided in severe acute attacks. It may be used cautiously in mild or less severe attacks as an adjunct to other measures, but should be discontinued promptly should abdominal distension or other untoward symptoms occur.

The stated dose should not be exceeded.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine because it contains lactose.

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Non-clinical data have shown that loperamide is a P-glycoprotein substrate. Concomitant administration of loperamide (16 mg single dose) with quinidine, or ritonavir, which are both P-glycoprotein inhibitors, resulted in a 2 to 3-fold increase in loperamide plasma levels. The clinical relevance of this pharmacokinetic interaction with P-glycoprotein inhibitors, when loperamide is given at recommended dosages, is unknown.

The concomitant administration of loperamide (4 mg single dose) and itraconazole, an inhibitor of CYP3A4 and P-glycoprotein, resulted in a 3 to 4-fold increase in loperamide plasma concentrations. In the same study a CYP2C8 inhibitor, gemfibrozil, increased loperamide by approximately 2-fold. The combination of itraconazole and gemfibrozil resulted in a 4-fold increase in peak plasma levels of loperamide and a 13-fold increase in total plasma exposure. These increases were not associated with central nervous system (CNS) effects as measured by psychomotor tests (i.e., subjective drowsiness and the Digit Symbol Substitution Test).

The concomitant administration of loperamide (16 mg single dose) and ketoconazole, an inhibitor of CYP3A4 and P-glycoprotein, resulted in a 5-fold increase in loperamide plasma concentrations. This increase was not associated with increased pharmacodynamic effects as measured by pupillometry.

Concomitant treatment with oral desmopressin resulted in a 3-fold increase of desmopressin plasma concentrations, presumably due to slower gastrointestinal motility.

It is expected that drugs with similar pharmacological properties may potentiate loperamide's effect and that drugs that accelerate gastrointestinal transit may decrease its effect.

Go to top of the page
4.6 Pregnancy and lactation

The safety of Imodium in human pregnancy has not been established. Small amounts of loperamide may appear in human breast milk. Therefore, Imodium is not recommended during breast feeding.

Women who are pregnant or breast feeding infants should therefore be advised to consult their doctor for appropriate treatment.

Go to top of the page
4.7 Effects on ability to drive and use machines

Tiredness, dizziness, or drowsiness may occur when diarrhoea is treated with Imodium. Therefore, it is advisable to use caution when driving a car or operating machinery. See section 4.8 Undesirable effects.

Go to top of the page
4.8 Undesirable effects

Adults and children aged ≥ 12 years

The safety of loperamide HCl was evaluated in 2755 adults and children aged ≥ 12 years who participated in 26 controlled and uncontrolled clinical trials of loperamide HCl used for the treatment of acute diarrhoea.

The most commonly reported (i.e. ≥ 1% incidence) adverse drug reactions (ADRs) in clinical trials with loperamide HCl in acute diarrhoea were: constipation (2.7%), flatulence (1.7%), headache (1.2%) and nausea (1.1%).

Table 1 displays ADRs that have been reported with the use of loperamide HCl from either clinical trial (acute diarrhoea) or post-marketing experience.

The frequency categories use the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); and very rare (<1/10,000).

Table 1: Adverse Drug Reactions

System Organ Class





Immune System Disorders


Hypersensitivity reactiona

Anaphylactic reaction (including Anaphylactic shock)a

Anaphylactoid reactiona

Nervous System Disorders




Loss of consciousnessa


Depressed level of consciousnessa


Coordination abnormalitya

Eye Disorders



Gastrointestinal Disorders




Abdominal pain

Abdominal discomfort

Dry mouth

Abdominal pain upper



Ileusa (including paralytic ileus)

Megacolona (including toxic megacolonb)

Abdominal distension

Skin and Subcutaneous Tissue Disorders



Bullous eruptiona (including Stevens-Johnson syndrome, Toxic epidermal necrolysis and Erythema multiforme)




Renal and Urinary Disorders


Urinary retentiona

General Disorders and Administration Site Conditions



a: Inclusion of this term is based on post-marketing reports for loperamide HCl. As the process for determining post marketing ADRs did not differentiate between chronic and acute indications or adults and children, the frequency is estimated from all clinical trials with loperamide HCl (acute and chronic), including trials in children ≤ 12 years (N=3683).

b: See section 4.4 Special Warnings and Special Precautions for use.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

Go to top of the page
4.9 Overdose

Overdose (relative or absolute) may lead to constipation, urinary retention, ileus and central nervous system depression (miosis, muscular hypertonia, somnolence and bradypnoea). Naloxone may be given as an antidote, repeated as necessary over an observation period of at least 48 hours.

Go to top of the page

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antipropulsives; ATC code: A07DA03

Loperamide binds to the opiate receptor in the gut wall, reducing propulsive peristalsis, increasing intestinal transit time and enhancing resorption of water and electrolytes. Loperamide increases the tone of the anal sphincter.

Go to top of the page
5.2 Pharmacokinetic properties

The half-life of loperamide in man is 10.8 hours with a range of 9-14 hours. Studies on distribution in rats show high affinity for the gut wall with preference for binding to the receptors in the longitudinal muscle layer. Loperamide is well absorbed from the gut, but is almost completely extracted and metabolised by the liver where it is conjugated and excreted via the bile. Due to its high affinity for the gut wall and its high first pass metabolism, very little loperamide reaches the systemic circulation. Excretion occurs mainly through the faeces.

Go to top of the page
5.3 Preclinical safety data

Not applicable.

Go to top of the page

Go to top of the page
6.1 List of excipient(s)

Capsule content


Maize starch


Magnesium stearate

Capsule cap

Titanium dioxide (E171)

Yellow ferric oxide (E172)

Indigotindisulphonate sodium (E132)


Capsule body

Titanium dioxide (E171)

Black ferrous oxide (E172)

Indigotindisulphonate sodium (E132)

Erythrosin (E127)


Go to top of the page
6.2 Incompatibilities

Not applicable.

Go to top of the page
6.3 Shelf life

5 years.

Go to top of the page
6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

Go to top of the page
6.5 Nature and contents of container

Imodium Capsules are packaged in blister packs consisting of polyvinylchloride, glass clear 250 µm and aluminium foil (thickness 20 µm) coating on the inner side with a colourless heat seal lacquer: PVC mixed polymers with acrylates 6 g/m2, in an outer cardboard carton.

The packs contain 60 capsules.

Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.

Go to top of the page

McNeil Healthcare (Ireland) Ltd.

Airton Road


Dublin 24


Go to top of the page

PA 823/56/3

Go to top of the page

14 April 1997 / 30 January 2009

Go to top of the page

October 2015

Link to this document from your website:

Document Links

  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients

   Loperamide Hydrochloride